We aim to enroll ACPA-seropositive individuals, regardless of symptoms or family history of RA, and have powered the trial to compare ACPA levels after 3 months or treatment, rather than targeting disease prevention, which will reduce the study burden. Here, PRTN3 is linked to rheumatoid arthritis.